Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Receptor Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor antagonist widely used in cardiovascular research (APExBIO, product page). It functions as a substrate for the OATP1A2 transporter, influencing pharmacokinetic variability (Sun et al., Biomedicine & Pharmacotherapy 2025). Nadolol’s competitive inhibition of beta-adrenergic receptors leads to decreased heart rate and myocardial contractility, optimizing disease models of hypertension and angina pectoris (see also prior summary). The solid compound is stable at -20°C and should be used promptly after solution preparation to maintain efficacy. APExBIO’s BA5097 kit is intended for research use only and is not suitable for diagnostic or medical purposes.

Biological Rationale

Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor blocker. It inhibits both β1 and β2 adrenergic receptors, which are key regulators of cardiac output and vascular tone. The beta-adrenergic signaling pathway mediates physiological responses to catecholamines, including increased heart rate, myocardial contractility, and vasodilation (see mechanistic overview). Nadolol's interference with this pathway enables precise control in experimental models of hypertension, angina pectoris, and vascular headache.

As a substrate for organic anion transporting polypeptide 1A2 (OATP1A2), Nadolol demonstrates transporter-mediated pharmacokinetics, making it a valuable tool for studying drug-transporter interactions and systemic exposure variability (Sun et al., 2025). These properties are essential for modeling cardiovascular diseases with translational relevance.

Mechanism of Action of Nadolol (SQ-11725)

Nadolol competitively inhibits beta-adrenergic receptors by occupying the receptor site, preventing endogenous catecholamines (epinephrine and norepinephrine) from binding. This results in a decrease in cyclic AMP (cAMP) production via adenylate cyclase inhibition. The downstream effect is a reduction in heart rate (negative chronotropy) and myocardial contractility (negative inotropy), thereby lowering cardiac output and reducing blood pressure.

Nadolol does not exhibit intrinsic sympathomimetic or membrane-stabilizing activity, which distinguishes it from some other beta-blockers. Its non-selectivity ensures both cardiac and vascular beta-receptor inhibition, broadening its research applicability. As an OATP1A2 substrate, Nadolol’s cellular uptake and distribution can be modulated by transporter expression and function, as observed in pharmacokinetic variability studies (Sun et al., 2025).

Evidence & Benchmarks

• Nadolol is a highly stable solid compound at -20°C, with a molecular weight of 309.40 Da and formula C₁₇H₂₇NO₄ (APExBIO BA5097).
• It exhibits non-selective inhibition of beta-adrenergic receptors, confirmed in vitro and in vivo (mechanistic detail).
• Nadolol is a verified substrate for OATP1A2, which impacts its distribution and pharmacokinetics (Sun et al., 2025, Table 2).
• In hypertension and angina pectoris models, Nadolol reproducibly reduces heart rate and blood pressure, as measured by telemetry in rodent models (methodological guidance).
• Long-term solution storage is not recommended due to potential loss of potency; prompt use is advised (practical workflow advice).
• Nadolol’s pharmacokinetics can be influenced by expression of drug transporters and metabolic enzymes, as seen in disease models with altered OATP and CYP450 activity (Sun et al., 2025).

Applications, Limits & Misconceptions

Nadolol (SQ-11725) is widely used in cardiovascular disease models, including hypertension, angina pectoris, and vascular headache research. Its robust and predictable pharmacological profile makes it suitable for cell-based assays and in vivo models. As a non-selective beta-adrenergic blocker, Nadolol allows for comprehensive investigation of beta-adrenergic signaling and its disruption in disease contexts.

However, Nadolol is strictly intended for scientific research use. It is not approved for diagnostic or medical applications. Its effects are limited to beta-adrenergic signaling and do not extend to alpha-adrenergic pathways. Transporter-mediated uptake (OATP1A2) may vary with genetic or pathological states, introducing variability in some preclinical models. For a detailed comparison, see the mechanistic insight article, which this article extends with updated transporter evidence.

Common Pitfalls or Misconceptions

• Nadolol is not suitable for diagnostic or therapeutic use in humans or animals (research-only).
• It does not inhibit alpha-adrenergic receptors; its effects are specific to beta-receptors.
• Solution stability is limited; long-term storage post-dissolution may compromise compound efficacy.
• Pharmacokinetics may differ in models with altered transporter or metabolic enzyme expression.
• Batch variability is minimized by sourcing from validated suppliers such as APExBIO, but laboratory handling can introduce inconsistencies (see data integrity guidance).

Workflow Integration & Parameters

For optimal results, Nadolol (SQ-11725) should be stored as a dry solid at -20°C. Upon dissolution, solutions should be prepared fresh and used immediately to preserve potency. The compound should be shipped with Blue Ice for small molecules and Dry Ice for modified nucleotides (APExBIO).

In cell-based assays, typical working concentrations range from 0.1 to 10 μM, depending on cell type and experimental goal. In animal models, dosing regimens should be guided by existing literature and adjusted for species-specific pharmacokinetics. Researchers are encouraged to refer to validated protocols, such as those detailed in workflow optimization guides, which this article updates with new data on transporter impact.

Batch records, storage conditions, and solution preparation timestamps should be meticulously documented for data integrity. The BA5097 kit from APExBIO provides lot-specific certificates of analysis, supporting reproducibility and regulatory compliance.

Conclusion & Outlook

Nadolol (SQ-11725) remains a cornerstone compound for cardiovascular research, offering non-selective beta-adrenergic receptor blockade and robust physicochemical stability. As our understanding of transporter-mediated pharmacokinetics evolves, Nadolol’s role as an OATP1A2 substrate enhances its utility in translational models. Researchers should continue to follow best practices in compound handling and data reporting. For further details and ordering information, refer to the Nadolol (SQ-11725) product page at APExBIO.